Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate
Pharmaceutics · 18.12.2025 · 17 (12) · 1627
DOI: 10.3390/pharmaceutics17121627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 18.12.2025. Verfasst von Ryo Ohashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Formulation R&D Laboratory, Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., 1-3 Kuise, Terajima 2-chome, Amagasaki 660-0813, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background/Objectives: S-892216 is a poorly water-soluble drug developed as a novel oral treatment for COVID-19, although its oral absorption is low. For Phase 1 (Ph1) studies and commercial use, both oral solution and solid dispersion technologies are evaluated to enhance drug solubility.
Methods
The solubility enhancement technology was selected by considering physicochemical factors such as stability and oral absorption, along with patient and customer acceptability.
Results
Pharmacokinetics study in rats revealed that both the polyethylene glycol 400 oral solution and polyvinylpyrrolidone-vinyl acetate (PVPVA) amorphous solid dispersion powder suspension showed almost 100% oral bioavailability. Therefore, they can be proposed as clinical formulations for Ph1 studies. PVPVA solid dispersion tablets were developed as a to-be-marketed formulation showed higher bioavailability in dogs than the anhydrous crystal formulation. Additionally, the stability of the developed solid dispersion tablet was acceptable.
Conclusions
This study demonstrates that multiple solubility enhancement technologies can be adopted for S-892216 development, and amorphous solid dispersion technology was selected for commercialization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Formulation R&D Laboratory, Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., 1-3 Kuise, Terajima 2-chome, Amagasaki 660-0813, Japan.
- Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., 1-1 Futaba-cho 3-chome, Toyonaka 561-0825, Japan.
ORCID-Profile: Ryo Ohashi, Ryosuke Watari
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Ohashi, R., Otake, S., Murata, T., Watari, R., Yoshida, S., Kitade, M., Kondo, D., & Kimura, G. (2025). Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics, 17(12), 1627. https://doi.org/10.3390/pharmaceutics17121627
Vancouver
Ohashi R, Otake S, Murata T, Watari R, Yoshida S, Kitade M, et al. Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics. 2025;17(12):1627. doi:10.3390/pharmaceutics17121627
BibTeX
@article{Ohashi2025,
author = {Ohashi, Ryo and Otake, Shuichi and Murata, Tatsuhiko and Watari, Ryosuke and Yoshida, Shinpei and Kitade, Mikiko and Kondo, Daisuke and Kimura, Go},
title = {Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {12},
pages = {1627},
doi = {10.3390/pharmaceutics17121627}
}
EUVIMED